Efficacy and safety of first-line avelumab treatment in patients with stage IV metastatic merkel cell carcinoma a preplanned interim analysis of a clinical trial

JAMA Oncology

Volumn 4, Issue 9, 2018, Pages

  D'Angelo, Sandra P ^a   Russell, Jeffery ^b   Lebbé, Céleste ^c   Chmielowski, Bartosz ^d   Gambichler, Thilo ^e   Grob, Jean Jacques ^f   Kiecker, Felix ^g   Rabinowits, Guilherme ^h   Terheyden, Patrick ⁱ   Zwiener, Isabella ^j   Bajars, Marcis ^k   Hennessy, Meliessa ^l   Kaufman, Howard L ^m,n  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d Immunocore Limited   (United Kingdom)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g RUHR UNIVERSITY BOCHUM   (Germany)

^h AIX MARSEILLE UNIVERSITY   (France)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j DANA FARBER CANCER INSTITUTE   (United States)

^k University of Löbeck   (Germany)

^l MERCK KGAA   (Germany)

^m EMD Serono   (United States)

ⁿ RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AVELUMAB; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; CHOLANGITIS; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENCEPHALOMYELITIS; FEMALE; FOLLOW UP; GAIT DISORDER; HUMAN; IMMUNOPATHOLOGY; INFUSION RELATED REACTION; MALE; MERKEL CELL CARCINOMA; METASTASIS; MONOTHERAPY; MULTICENTER STUDY; PARANEOPLASTIC SYNDROME; POLYNEUROPATHY; PROGRESSION FREE SURVIVAL; VERY ELDERLY; CLINICAL TRIAL; FATIGUE; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; PHASE 2 CLINICAL TRIAL; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SKIN TUMOR; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CARCINOMA, MERKEL CELL; FATIGUE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 85048840491     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2018.0077     Document Type: Article

References (15)

1. Schadendorf D, Lebbé C, Zur Hausen A, et al. Merkel cell carcinoma: epidemiology, prognosis, therapy and unmet medical needs. Eur J Cancer. 2017;71:53-69.
2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Merkel Cell Carcinoma, version 1. https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician-gls/pdf/mcc.pdf. Updated 2017. Accessed October 19, 2017.
3. Nghiem P, Kaufman HL, Bharmal M, Mahnke L, Phatak H, Becker JC. Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma. Future Oncol. 2017;13(14): 1263-1279.
4. Cowey CL, Mahnke L, Espirito J, Helwig C, Oksen D, Bharmal M. Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA. Future Oncol. 2017;13(19):1699-1710.
5. Iyer JG, Blom A, Doumani R, et al. Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma. Cancer Med. 2016;5(9):2294-2301.
6. Lipson EJ, Vincent JG, Loyo M, et al. PD-L1 expression in the Merkel cell carcinoma microenvironment: Association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res. 2013;1(1):54-63.
7. Schadendorf D, Nghiem P, Bhatia S, et al. Immune evasion mechanisms and immune checkpoint inhibition in advanced Merkel cell carcinoma. Oncoimmunology.2017;6(10):e1338237.
8. Terheyden P, Becker JC. New developments in the biology and the treatment of metastatic Merkel cell carcinoma. Curr Opin Oncol. 2017;29(3):221-226.
9. Nghiem PT, Bhatia S, Lipson EJ, et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med. 2016;374(26): 2542-2552.
10. Topalian SL, Bhatia S, Hollebecque A, et al. Non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-Associated tumors (CheckMate 358): efficacy and safety in Merkel cell carcinoma (MCC). Cancer Res. 2017;77(13 suppl):Abstract CT074.
11. Kaufman HL, Russell J, Hamid O, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: A multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17(10):1374-1385.
12. Bavencio (avelumab) injection [package insert]. Darmstadt, Germany: Merck KGaA; 2017.
13. European Commission approves Bavencio (avelumab) for metastatic Merkel cell carcinoma. Darmstadt, Germany: Merck KGaA and Pfizer Inc; September 21, 2017. https://www.pfizer.com/news/press-release/press-release-detail/european-commission-Approves-bavencio-Avelumab-for-metastatic-merkel-cell-carcinoma. Accessed October 8, 2017.
14. Bavencio (avelumab) approved for Merkel cell carcinoma in Japan. Darmstadt, Germany: Merck KGaA and Pfizer Inc; September 21, 2017. https://www.pfizer.com/news/press-release/press-release-detail/bavencio-Avelumab-Approved-for-merkel-cell-carcinoma-in-japan. Accessed October 8, 2017.
15. Kaufman HL, Russell JS, Hamid O, et al. Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after-1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. J Immunother Cancer. 2018;6:7.